Header Logo

Connection

Debra Richardson to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about Neoplasm Recurrence, Local.
Debra Richardson
Connection Strength
3.594
Neoplasm Recurrence, Local
  1. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
    View in: PubMed
    Score: 0.494
  2. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
    View in: PubMed
    Score: 0.477
  3. Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. Gynecol Oncol. 2009 Nov; 115(2):306-7.
    View in: PubMed
    Score: 0.263
  4. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
    View in: PubMed
    Score: 0.250
  5. Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51.
    View in: PubMed
    Score: 0.236
  6. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug; 34(8):1283-1289.
    View in: PubMed
    Score: 0.192
  7. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
    View in: PubMed
    Score: 0.187
  8. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
    View in: PubMed
    Score: 0.185
  9. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):1-5.
    View in: PubMed
    Score: 0.165
  10. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.160
  11. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
    View in: PubMed
    Score: 0.147
  12. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.
    View in: PubMed
    Score: 0.125
  13. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299.
    View in: PubMed
    Score: 0.124
  14. Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2018 05; 41(5):447-451.
    View in: PubMed
    Score: 0.121
  15. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.115
  16. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
    View in: PubMed
    Score: 0.086
  17. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
    View in: PubMed
    Score: 0.074
  18. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
    View in: PubMed
    Score: 0.072
  19. Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):6-14.
    View in: PubMed
    Score: 0.042
  20. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747.
    View in: PubMed
    Score: 0.036
  21. Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
    View in: PubMed
    Score: 0.026
  22. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.